Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 1
1968 1
1969 3
1970 4
1971 1
1974 1
1975 3
1976 3
1977 1
1978 1
1979 6
1980 2
1981 7
1982 3
1983 3
1984 3
1985 3
1986 5
1987 15
1988 15
1989 22
1990 24
1991 24
1992 25
1993 42
1994 39
1995 82
1996 147
1997 173
1998 175
1999 157
2000 164
2001 199
2002 239
2003 259
2004 282
2005 312
2006 266
2007 267
2008 368
2009 344
2010 380
2011 405
2012 473
2013 501
2014 474
2015 541
2016 453
2017 424
2018 436
2019 240
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

7,215 results
Results by year
Filters applied: . Clear all
Page 1
Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions
Schett G, et al. Ann Rheum Dis 2016 - Review. PMID 27261493 Free article.
Improvements in the control of inflammation in rheumatoid arthritis (RA) by conventional synthetic and biologic disease-modifying antirheumatic drugs (DMARDs) have led to a substantial change in the clinical outcomes of patients during the last 30 years. ...
Improvements in the control of inflammation in rheumatoid arthritis (RA) by conventional synthetic and biologic disease-modifying antirhe
Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors.
Betancourt BY, et al. Rheum Dis Clin North Am 2018 - Review. PMID 30001781 Free PMC article.
Oral disease-modifying antirheumatic drugs, including methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide, and the small molecule inhibitors tofacitinib and apremilast have distinctive monitoring requirements and specific adverse reaction profiles. ...
Oral disease-modifying antirheumatic drugs, including methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide, and the small …
[Hyperuricemia. When and how to treat?]
Reuss-Borst MA. Internist (Berl) 2016 - Review. PMID 26791735 German.
Current concepts in the management of rheumatoid arthritis
Tanaka Y. Korean J Intern Med 2016 - Review. PMID 26932398 Free PMC article.
However, the combined use of methotrexate, a synthetic disease-modifying antirheumatic drug (DMARD), and biologic DMARD has revolutionized treatment of RA. ...
However, the combined use of methotrexate, a synthetic disease-modifying antirheumatic drug (DMARD), and biologic DMARD has revolutio …
Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature
Chen DY, et al. Int J Rheum Dis 2018 - Review. PMID 29205904
METHODS: Published studies conducted in patients with RA that sequentially decreased the dose and then discontinued therapy were included if one or more of the following biologic disease modifying antirheumatic drugs (bDMARDs) was evaluated: abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab or tocilizumab. ...
METHODS: Published studies conducted in patients with RA that sequentially decreased the dose and then discontinued therapy were included if …
7,215 results
Jump to page
Feedback